3085 results for "Psilocybin"
Beyond LSD: A Broader Psychedelic Zeitgeist during the Early to Mid-20thCentury
Journal of Psychoactive Drugs – March 06, 2019
Summary
The prevailing view that LSD's 1943 discovery solely fueled the 1950s-1960s psychedelic research boom is incomplete. A broader zeitgeist in the history of psychology paved the way. Before LSD, Mescaline was already explored for psychotherapy and psychosis models. Psilocybin, another hallucinogen, also emerged. Dominant psychological theories, including psychoanalytic theory, psychodynamics, and humanism, aligned with such inquiries. This historiography highlights how the chemical synthesis of various alkaloids contributed to a rich period for Psychedelics and Drug Studies, influencing psychotherapists and even Complementary and Alternative Medicine Studies, beyond just one drug.
Abstract
During the 1950s and 1960s, there was a tremendous surge in research into the effects of psychedelic drugs. When discussing this period of research...
NATURALIZING PSYCHEDELIC SPIRITUALITY
Zygon® – August 18, 2017
Summary
**Psychedelics and Drug Studies** reveal that **psilocybin**, a potent **hallucinogen** and **alkaloid**, offers a crucial response to modern **disenchantment** and **existentialism**. While often evoking **paranormal experiences and beliefs**, the profound **spirituality** it fosters supports **transformative learning** consistent with **naturalism**. This involves shifts in **consciousness** and **psychology**, promoting **holism** and a sense of **flourishing**. Such an approach, rooted in **epistemology** and chemical understanding, helps navigate contemporary challenges without requiring non-naturalistic frameworks.
Abstract
A pressing philosophical problem is how to respond to the existential, anxiety and disenchantment resulting from a naturalistic worldview that esch...
Is the Requirement for First-Person Experience of Psychedelic Drugs a Justified Component of a Psychedelic Therapist’s Training?
Cambridge Quarterly of Healthcare Ethics – March 02, 2023
Summary
Psychedelics like Psilocybin and MDMA show significant therapeutic potential for conditions from addiction to existential distress, marking a potential step change in Psychiatry. While their value stems from unique experiential learning, questions arise regarding psychotherapist training. Should future psychotherapists undergo hallucinogen experiences themselves? Current thinking suggests requiring such firsthand engagement isn't ethically legitimate without stronger evidence of its unique contribution to understanding psychology. However, permitting voluntary participation in Psychedelics and Drug Studies might be acceptable, acknowledging the diverse academic research themes involved.
Abstract
Abstract Recent research offers good reason to think that various psychedelic drugs—including psilocybin, ayahuasca, ketamine, MDMA, and LSD—may ha...
Hallucinogen persisting perception disorder: A literature review and three case reports
Journal of Addictive Diseases – October 02, 2018
Summary
More than 50% of hallucinogen users may experience persistent perception disorder, a condition often underdiagnosed in Psychiatry and Psychology. This involves visual hallucination. Three cases illustrate types: a 23-year-old developed symptoms after Psilocybin and Cannabis, recurring with natural cannabinoids. Surprisingly, two others developed severe visual impairments after Ecstasy (MDMA), despite it not being a typical hallucinogen. Clinicians in Medicine and Psychedelics and Drug Studies, including Forensic Toxicology and Drug Analysis, need awareness, relevant to Cannabis and Cannabinoid Research.
Abstract
The paper describes diagnostic criteria, clinical presentation and types of hallucinogen persisting perception disorder (HPPD), as well as current ...
Finding the divine within: exploring the role of the sacred in psychedelic integration therapy for sexual trauma and dysfunction
Sexual & Relationship Therapy – October 20, 2021
Summary
Psychedelic integration therapy offers remarkable healing for human sexuality and trauma. Guided by a psychotherapist, individuals using natural compounds like psilocybin report profound embodied pleasure, liberated from shame. This psychological approach fosters a healthy identity and increased sexual satisfaction, addressing deep-seated issues that can underpin addiction. Clients describe direct, existential meaning through divine connection, facilitating sustained well-being. This innovative area within psychedelics and drug studies holds significant promise.
Abstract
During the last two decades, psychedelic-assisted therapy has emerged as one of the most promising novel treatments for depression, anxiety, PTSD, ...
Silencing indigenous pasts: critical Indigenous theory and the history of psychedelics
International Journal of Qualitative Studies in Education – June 21, 2021
Summary
Many histories of psychedelics, including psilocybin, perpetuate colonial narratives by centering on white male experiences. Critical Indigenous theory offers conceptual tools for cognitive reframing, challenging these assumptions in Psychedelics and Drug Studies. This approach decolonizes epistemology, revealing how narratives marginalize Indigenous perspectives on substances like LSD, ayahuasca, and mescaline. Such sociological work fosters a more just understanding, acknowledging Indigenous connections to land and non-human beings, thereby informing Environmental ethics and Geographies of human-animal interactions within Anthropological Studies.
Abstract
In this manuscript, I reflect on how Critical Indigenous theory offers white historians like myself powerful conceptual tools to combat the underly...
Migraine prevalence in visual snow with prior illicit drug use (hallucinogen persisting perception disorder) versus without
European Journal of Neurology – May 12, 2021
Summary
Strikingly, no migraine was found in 24 individuals experiencing visual snow syndrome after illicit drug use. In contrast, 20 of 37 (54.1%) controls with visual snow but no prior drug use suffered from migraine. This finding, relevant for Medicine and Psychiatry, suggests distinct underlying factors. Most visual snow cases (70.9%) followed Ecstasy intake, with Cannabis and Psilocybin also implicated. Drug Studies highlight the importance of understanding these psychedelics' effects, particularly for Migraine and Headache Studies. Users of hallucinogens should be aware of visual snow risks.
Abstract
Abstract Background and purpose This study was undertaken to investigate migraine prevalence in persons with hallucinogen persisting perception dis...
A persisting perception disorder after cannabis use
Progress in Neurology and Psychiatry – January 01, 2015
Summary
A compelling finding in Psychology and Medicine challenges our understanding of drug-induced disorders. While Hallucinogen persisting perception disorder (HPPD) is typically linked to classical Psychedelics like Psilocybin and Mescaline, a recent case suggests a broader etiology. A single boy developed HPPD-like symptoms after using Cannabis just seven times. This observation, relevant for Psychedelics and Drug Studies, as well as Cannabis and Cannabinoid Research, prompts new questions in Psychiatry regarding Perception and Forensic Toxicology and Drug Analysis, indicating potential links beyond traditional hallucinogens.
Abstract
Hallucinogen persisting perception disorder is a disorder of uncertain aetiology occurring mainly after ‘classical’ hallucinogen use ( ie mescaline...
The Psychotomimetic Drugs
JAMA – March 07, 1964
Summary
Psychedelics profoundly reshape human consciousness, revealing the mind's capacity for extraordinary experiences. Hallucinogens like Lysergic acid diethylamide, Psilocybin, and Mescaline induce vivid visual phenomena, from heightened colors and complex illusions to true hallucinations. Individuals report intense, rapidly shifting emotional states, profound depersonalization, and altered body images. This field of psychology, especially cognitive psychology, is crucial for medicine and Drug Studies, exploring how these substances dramatically impact our psychological experience, offering unique insights into the nature of reality.
Abstract
FOR MANY YEARS several pharmacologically similar drugs—lysergic acid diethylamide (LSD-25), psilocybin, and mescaline, among others—have been of sp...
Ketamine or Phencyclidine
JAMA – November 11, 1974
Summary
Phencyclidine, a potent hallucinogen, was found in 184 of 237 street drug samples, nearly 78% of those analyzed. This widespread presence, often misrepresented as Mescaline or Psilocybin, highlights a significant problem in Psychedelics and Drug Studies. Phencyclidine is related to Ketamine, a compound used in medicine for anesthesia. Understanding its pharmacology, particularly its Neurotransmitter Receptor Influence on Behavior, is crucial. Forensic Toxicology and Drug Analysis are vital to identify this drug, which induces symptoms like visual distortions and psychosis, distinguishing it from other psychedelics.
Abstract
To the Editor.— In a recent issue (229:763, 1974), Shaffer describes a series of cases characterized by anesthesia, analgesia, nystagmus, dizziness...
Analytical Procedures Used in FDA Laboratories for theAnalysis of Hallucinogenic Drugs
Journal of AOAC INTERNATIONAL – January 01, 1968
Summary
Accurate identification of hallucinogenic drugs is crucial for public safety and medical applications. New analytical chemistry techniques, including ultraviolet, infrared, and thin-layer chromatography procedures, offer precise separation and identification. Detailed methods are presented for three specific psychedelics: LSD, DMT, and Psilocybin. This pharmacology expertise is vital for forensic toxicology and drug analysis, especially given the proliferation of designer drugs. Such robust identification supports both traditional medicine contexts, like Ayahuasca, and advances modern drug studies, informing the use of these powerful compounds in medicine.
Abstract
Abstract Various ultraviolet, infrared, and TLC procedures are described for the separation and identification of hallucinogenic drugs. Specific me...
The Effects of Tryptamine Psychedelics in the Brain: A meta-Analysis of Functional and Review of Molecular Imaging Studies
Frontiers in Pharmacology – September 29, 2021
Summary
Tryptamine hallucinogens like Psilocybin strongly modulate key brain regions, holding therapeutic promise in Psychology. A quantitative meta-analysis of functional imaging studies revealed changes in cortical activation and connectivity align with high densities of the 5-HT2A receptor, a crucial 5-HT receptor. Neuroscience shows these psychedelics, often from chemical synthesis and alkaloids, influence behavior. Affected areas include the anterior cingulate cortex, posterior cingulate, ventromedial prefrontal cortex, dorsolateral prefrontal cortex, and temporal cortex. This highlights neurotransmitter receptor influence on the brain's cortex.
Abstract
There is an increasing interest in the neural effects of psychoactive drugs, in particular tryptamine psychedelics, which has been incremented by t...
Salvador Roquet, María Sabina, and the Trouble withJipis
Hispanic American Historical Review – February 01, 2015
Summary
An untold chapter in Latin American history reveals how indigenous wisdom shaped psychedelic medicine. Psychiatrist Salvador Roquet, collaborating with the iconic Indigenous healer María Sabina, developed a therapeutic method for psychedelics, including psilocybin mushrooms. Their unique cross-cultural exchange, an important insight for Anthropological Studies and Drug Studies, challenged the prevailing counterculture narrative. Unlike the "jipis," they viewed these substances as potent medicines requiring expert, respectful handling. This perspective offers a rich contribution to our understanding of psychedelic use, rooted deeply in Latin American culture and contrasting with popular sociology.
Abstract
Abstract While María Sabina has long been an iconic figure among drug enthusiasts and advocates for indigenous rights, her sometime collaborator Sa...
ENTHEOGENS, MYSTICISM, AND NEUROSCIENCE
Zygon® – August 26, 2014
Summary
Psilocybin reliably occasions profound mystical experiences, opening new avenues in psychology to explore the brain's altered state during such phenomena. This allows for critical drug studies into the neurotransmitter receptor influence on behavior. Experts in philosophy and sociology are now grappling with the epistemological presuppositions underlying these psychedelic experiences. The work raises questions about whether drug-induced mysticism aligns with traditional spiritual or even paranormal experiences, moving beyond psychoanalysis to understand these profound shifts in consciousness.
Abstract
Entheogens or psychedelic drugs such as lysergic acid diethylamide (LSD) and psilocybin are associated with mystical states of experience. Drug law...
Advances in Psychedelic Medicine
OpenAlex – January 01, 2019
Summary
Psychedelics are rapidly transforming Medicine, with the U.S. government lifting its testing ban over a decade ago. Substances like Psilocybin, MDMA, and the hallucinogen Ayahuasca are now being integrated into Psychiatry and Psychology, augmenting psychotherapies for conditions like Addiction and depressive disorders. This comprehensive assessment covers clinical efficacy, safety, and ethical considerations, alongside neuroscience findings. It also explores microdosing, cannabinoid research, and training future psychotherapists in this evolving field of Psychedelics and Drug Studies.
Abstract
Researchers, program administrators, and practicing clinicians explain the most recent developments in using psychedelic substances to treat psycho...
Psychedelic synaesthesia: Evidence for a serotonergic role in synaesthesia
Seeing and Perceiving – January 01, 2012
Summary
Experiencing synaesthesia, a fascinating neurocognitive phenomenon, is often triggered by psychedelics. A survey of recreational drug users in Psychedelics and Drug Studies found that serotonergic hallucinogens like Lysergic acid diethylamide (LSD) and Psilocybin frequently induce these unique sensory blends. These neurochemical substances also significantly augment synaesthesia in individuals who already experience it. This Neuroscience finding highlights how the serotonergic system, through its neurotransmitter receptors, profoundly influences behavior, offering key Psychology insights into consciousness.
Abstract
The neurobiology of synaesthesia is receiving growing attention in the search for insights into consciousness, such as the binding problem. One way...
Accounting for Microdosing Classic Psychedelics
Journal of Drug Issues – August 30, 2019
Summary
Remarkably, individuals who microdose psychedelics, like chemically synthesized LSD and natural psilocybin, never excuse their practice. All 30 interviewed offered justifications, a key insight for Social psychology. This Psychology research shows users employ "Denial of injury" and "Appeal to normality" to align their actions with societal expectations, even considering the substances' status in Drug Studies and potential for Forensic Toxicology.
Abstract
Microdosing classic psychedelics (e.g., LSD [lysergic acid diethylamide] and psilocybin) is the practice of taking small amounts of these substance...
Psychedelic experiences and long-term spiritual growth: a systematic review
Current Psychology – July 12, 2024
Summary
Psychedelics, including psilocybin, significantly foster long-term spiritual growth, a systematic Psychology review of 34 studies involving 19,724 participants reveals. These substances, often associated with profound religious experience and Mysticism, enhance feelings of unity and Transcendence, deepen spiritual Faith, and boost Social connectedness. Individuals report stronger divine connections, increased meaning, and greater engagement in Spirituality. This suggests a powerful link between certain Chemical synthesis and alkaloids and an individual's Religiosity and overall well-being, influencing their religious orientation.
Abstract
Abstract Psychedelic substances, which can occasion mystical experiences, are sometimes used for religious and spiritual reasons. Despite strong li...
Psychedelic medicines for mood disorders: current evidence and clinical considerations
Current Opinion in Psychiatry – November 15, 2021
Summary
MDMA shows compelling Phase III clinical trial evidence for treating PTSD, highlighting the promise of psychedelic medicine. Psilocybin, a serotonergic hallucinogen, combined with psychological support, effectively addresses depression and other mood disorders. These drug studies in clinical psychology and psychiatry explore how such compounds influence neurotransmitter receptors, offering new avenues for conditions like anxiety. While promising, current medicine often involves small sample sizes.
Abstract
Purpose of review Despite advances in treatment modalities for mood disorders over recent decades, further therapeutic options are still required. ...
Jekyll and Hyde Revisited: Paradoxes in the Appreciation of Drug Experiences and Their Effects on Creativity
Journal of Psychoactive Drugs – September 01, 2002
Summary
Paradoxically, psychedelic experiences, like those from psilocybin, often evoke simultaneous feelings of both "possession" by an external agency and profound liberation. While social psychology typically divides these into two opposed cultural interpretations—either revealing hidden truths or being under an irrational influence—the reality for artists engaged in creativity, as seen in visual culture, suggests a complex interplay. Experiential learning shows aesthetic traits in art reflecting both extremes, bridging the "demoniacal" and "psychedelic" in a single psychological reality, challenging our epistemology.
Abstract
Historically, states of intoxication--like dreams and madness--are seen in either one of two opposed ways. The intoxicated are either "possessed" o...
HALLUCINOGENIC AGENTS
JAMA – September 14, 1963
Summary
A growing medical and social problem involves the ingestion of drugs drastically altering sensory perception. Public interest is increasing in psychotomimetic hallucinogens like Psilocybin, Mescaline, and Lysergic acid diethylamide. Even morning-glory seeds, containing lysergic acid, are now used. While traditional medicine has long seen such substances, a new wave of promotion targets the general public. This trend, involving six distinct hallucinogens, highlights a significant challenge. Understanding their pharmacology, from ancient use to modern forms, is crucial for medicine.
Abstract
An article on stramonium intoxication in this issue ofThe Journal(p 882) calls attention to a growing medical and social problem in this country—th...
Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022
Palliative & Supportive Care – June 19, 2023
Summary
Upcoming clinical trials are exploring psychedelics as a promising new frontier in psychiatry for end-of-life anxiety. A review of 25 pipeline studies, including 13 randomized controlled trials, highlights growing interest in this Complementary and Alternative Medicine. Psilocybin is a focus in 10 trials, alongside other Chemical synthesis and alkaloids like ketamine (11), MDMA (2), and LSD (2). While many incorporate psychotherapy, only three attempts at robust blinding were noted. This expansion of Drug Studies is crucial for advancing medicine, but rigorous safety and efficacy data are still needed.
Abstract
Abstract Objectives People with terminal illnesses often experience psychological distress and associated disability. Recent clinical trial evidenc...
Psychotropic Drug-Induced Transformations of Visual Space
International Pharmacopsychiatry – January 01, 1971
Summary
Potent **drugs** like psilocybin and D-amphetamine significantly impair our brain's ability to perceive **space** accurately, lowering thresholds for visual distortion. This **pharmacology** reveals certain **medicine** hinders the mind's natural counter-adaptation to optical distortions, potentially explaining aspects of **hallucinations in medical conditions**. Conversely, the **drug** chlorpromazine promotes this visual optimization. This interference with perception operates independently of how quickly distorting stimuli are presented, highlighting subcortical influences on our visual interpretation processes.
Abstract
It was found that ergotropic arousal-inducing drugs, such as psilocybin, a Ditran®-type 'glycolate' and D-amphetamine, significantly lower human sp...
A Complex Impact of Systemically Administered 5-HT2A Receptor Ligands on Conditioned Fear
The International Journal of Neuropsychopharmacology – July 05, 2021
Summary
Psychedelics like psilocybin significantly reduced conditioned fear in male rats, relevant for **Psychology** and **Drug Studies**. **Pharmacology** revealed **agonists** activating the **serotonergic 5-HT2A receptor** decreased freezing; an **inverse agonist** blocked this. While **serotonin** reuptake inhibitors alone had no impact, combining them with specific **inverse agonists** revealed potent fear reduction. This complex **Neurotransmitter Receptor Influence on Behavior** involving various **5-HT receptors** like the **5-HT1A receptor**, holds implications for **Medicine**, including **Internal Medicine** and drug **Chemistry**, and **neuroendocrine regulation**, relevant to **Endocrinology**.
Abstract
Abstract Background Though drugs binding to serotonergic 5-HT2A receptors have long been claimed to influence human anxiety, it remains unclear if ...
Designer Drugs 2.0
Clinical Pharmacology & Therapeutics – January 13, 2017
Summary
Synthetic cannabinoids, potent Designer drugs, demonstrate significantly higher potency at Cannabinoid Receptor Agonists than natural compounds. This Neuropharmacology highlights novel psychoactive substances' dual nature and Medicine Repurposing, including Psilocybin and the Hallucinogen Lysergic acid diethylamide. Despite therapeutic promise for Psychology, illicit use, Psychosis, and Forensic Toxicology challenges remain critical for these drugs. This complex Pharmacology field, explored in Cannabis and Cannabinoid Research and Psychedelics and Drug Studies, addresses these issues.
Abstract
This “Designer Drugs 2.0” issue of Clinical Pharmacology & Therapeutics focuses on novel psychoactive substances, primarily cannabinoids and ca...
Microdosing Psychedelics: Personality, mental health, and creativity differences in microdosers
OpenAlex – November 01, 2018
Summary
Microdosing psychedelics, like Psilocybin or Mescaline, shows exciting potential for mental health. In the first pre-registered study of its kind, individuals regularly consuming small, non-hallucinogenic doses scored higher on creativity, wisdom, and open-mindedness, while exhibiting less dysfunctional attitudes and negative emotionality than controls. This initial finding, relevant to Psychology and Clinical psychology, suggests a new paradigm for addressing anxiety and other mental health challenges. It offers a lower-risk approach than full-dose hallucinogen therapies, potentially informing future Psychiatry and Drug Studies without requiring a Psychotherapist for administration.
Abstract
Microdosing psychedelics - the regular consumption of small amounts of psychedelic substances such as LSD or psilocybin - is a growing trend in pop...
Psychedelic use predicts objective knowledge about climate change via increases in nature relatedness
Drug Science Policy and Law – January 01, 2022
Summary
Psychedelics, particularly psilocybin, directly predict objective knowledge about climate change and indirectly boost concern through increased nature relatedness. This Psychology and Drug Studies insight, from an international survey of 641 participants, suggests the link between substance use and environmental change isn't merely a social psychology bias. Instead, it manifests as genuine ecological affinity and climate knowledge, challenging previous assumptions about self-report limitations. The findings highlight a unique connection between psychedelics and pro-environmental variables, impacting our understanding of environmental psychology.
Abstract
Lifetime psychedelic substance use has previously been linked to nature relatedness and pro-environmental behaviour. Yet, participants’ responses t...
Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives
Transcultural Psychiatry – August 29, 2022
Summary
Microdosing classical hallucinogens like Psilocybin and Lysergic acid diethylamide is a burgeoning trend, despite limited formal drug studies. While macrodosing effects are well-documented, microdosing involves intermittent, sub-perceptual doses, reportedly enhancing cognition and mental function. Many claim it's a therapeutic intervention, improving psychology without full "trips." This exploration synthesizes the social and clinical context of this practice, examining its potential as a psychotherapist-guided tool versus recreational use. Understanding these substances, often products of chemical synthesis, requires biochemical analysis to discern their true impact.
Abstract
To date, the clinical and scientific literature has best documented the effects of classical psychedelics, such as lysergic acid diethylamide (LSD)...
Wasson's Alternative Candidates for Soma
Journal of Psychoactive Drugs – April 01, 1993
Summary
R. Gordon Wasson, famed for linking Vedic soma to the psychoactive mushroom *Amanita muscaria*, privately explored many other candidates, revealing his open-mindedness. Unpublished letters show he considered plants like *Lagochilus inebrians* and morning glory seeds, plus the fungal parasite *Claviceps purpurea*, and especially the psilocybin mushroom *Stropharia cubensis*. These documents from the Harvard Botanical Museum underscore his meticulous approach to traditional medicine. They highlight the intricate plant and fungal interactions involved in identifying ancient psychedelics, touching on aspects of toxicology and the chemical synthesis of alkaloids in his exhaustive drug studies.
Abstract
Citing recently published challenges to R. Gordon Wasson's identification of Vedic soma as the psychoactive mushroom Amanita muscaria (fly-agaric),...
Nothing Ventured, Nothing Gained: Regulations Cripple Potentially Life-Saving Research of Illicit Substances
ACS Chemical Neuroscience – May 12, 2020
Summary
Regulations designed to prevent harm from substances like Psilocybin and Lysergic acid diethylamide severely cripple scientific progress. These rules make it nearly impossible to acquire illicit hallucinogens for vital research, achieving nothing but hindering potential life-saving discoveries. Reclassifying these compounds would unlock critical advancements in Pharmacology, impacting fields from Psychedelics and Drug Studies to Cannabis and Cannabinoid Research and even Forensic Toxicology and Drug Analysis. This regulatory business currently stifles crucial scientific inquiry.
Abstract
Modern day research, in an attempt to determine the potential therapeutic and adverse effects of illicit substances, is a growing field, but one th...
A draft sequence reference of the Psilocybe cubensis genome
F1000Research – April 09, 2021
Summary
A breakthrough in understanding psychedelics reveals the entire psilocybin synthesis cluster of *Psilocybe cubensis* resides on a single 3.2Mb contig. This advance in computational biology and genetics, achieved through whole genome sequencing, provides the complete 46.6Mb genome, assembled into 32 contigs with 97.6% completeness. Such detailed biology is crucial for Psychedelics and Drug Studies, offering unprecedented insights into chemical synthesis and alkaloids, and accelerating research into alkaloids: synthesis and pharmacology.
Abstract
We describe the use of high-fidelity single molecule sequencing to assemble the genome of the psychoactive Psilocybe cubensis mushroom. The genome ...
Have Effective Antidepressants Finally Arrived? Developments in Major Depressive Disorder Therapy
The Journal of Clinical Psychiatry – August 09, 2023
Summary
Innovative treatments are revolutionizing psychiatry, offering new antidepressant options for major depressive disorder, especially for those resistant to current medicine. Ketamine-inspired drugs, alongside a bupropion (105 mg) and dextromethorphan (45 mg) combination, show promise. Neurosteroids modulating GABA also represent a new class. Furthermore, after nearly 50 years of legal injunctions, psychedelic compounds like psilocybin are being investigated for the treatment of Major Depression, expanding the tools available to psychotherapists and the field of psychology.
Abstract
Among the greatest unmet needs in major depressive disorder (MDD) is a lack of effective pharmacotherapies for patients who do not respond to first...
A roadmap for psychedelic pharmacy in Canada: A proposed policy and operations approach for controlled access to select psychedelics for treatment of mental illness
Drug Science Policy and Law – January 01, 2023
Summary
The burgeoning field of psychedelic medicine, particularly psilocybin for mental illness, necessitates immediate action from health care leadership and the legislature. The pharmacy profession, surprisingly, has been largely disengaged. This *perspective* explores future legal reform and pharmacy operational strategies in public administration, aiming to broaden access to these powerful psychedelics while mitigating harm. Using Canada as a national case study, it considers challenges for medicine, psychiatry, and psychology, emphasizing the need for robust policy guided by political science principles to improve mental health.
Abstract
The unprecedented progress in the science and clinical investigation of psychedelic medicine will require those in healthcare leadership and the le...
Should Adolescents be Included in Emerging Psychedelic Research?
Canadian Journal of Bioethics – January 01, 2022
Summary
Psychedelic substances like psilocybin show significant promise for adult mental health, yet adolescent inclusion in psychological intervention trials is currently 0%. A compelling argument highlights the urgent need for novel medical interventions to address growing youth mental health burdens. Psychedelics pose low risk compared to existing psychiatric medications. While developmental risks and informed consent complexities exist, including adolescents in clinical psychology and drug studies is crucial. This would improve their quality of life, offering innovative treatments and advancing diverse academic research themes in medicine and psychology.
Abstract
Recent evidence shows significant potential for therapies involving psychedelic substances such as psilocybin and MDMA to improve clinical outcomes...
The use of psychedelics in the treatment of disorders of consciousness. An interview with Olivia Gosseries by Charlotte Martial.
Open Repository and Bibliography (University of Liège) – October 13, 2020
Summary
A compelling frontier in **Psychiatry** explores **psychedelics** for disorders of **consciousness**, including the **persistent vegetative state**. Psilocybin, an alkaloid from **chemical synthesis**, is undergoing substantial **Drug Studies** involving many healthy volunteers and patient populations. Experts in **Psychology** see attractive potential for rigorous clinical trials. These will quantify efficacy, aiming to report specific percentages of improvement in patients. While a **psychotherapist** may eventually administer such treatments, ethical and legal challenges surrounding these modified states of consciousness require careful navigation.
Abstract
In this interview, we discuss the use of psychedelic drugs as a promising treatment in disorders of consciousness. Psilocybin, a classic psychedeli...
Drug use and hypnotic susceptibility
International Journal of Clinical and Experimental Hypnosis – January 01, 1972
Summary
Individuals who have experimented with hallucinogens like psilocybin or mescaline exhibit greater hypnotic susceptibility. Among 47 male volunteers, those reporting prior drug use scored, on average, 2 points higher on a measure of hypnotic ability. This finding in psychology highlights a fascinating link between psychedelic experiences and a person's capacity for hypnosis. Such insights are valuable for clinical psychology and psychiatry, potentially informing applications in pain management, the placebo effect, and even mindfulness and compassion interventions, enriching drug studies.
Abstract
Abstract 47 undergraduate male volunteers were asked 2 questions relating to their use of marijuana and/or psychedelic drugs (e.g., LSD, mescaline,...
Mapping Pharmacologically-induced Functional Reorganisation onto the Brain’s Neurotransmitter Landscape
OpenAlex – July 13, 2022
Summary
Mind-altering drugs profoundly reorganize brain function by engaging intricate neurotransmitter systems. Neuroscience and Neuropharmacology Research demonstrates that psychoactive substances, including 10 diverse drugs like psychedelics (LSD, psilocybin) and anesthetics, exert their effects based on the brain's molecular makeup. By mapping 19 neurotransmitter receptors and transporters, a clear link emerged between specific neurotransmitter receptor influence on behavior and drug-induced changes. This work in Psychology and Medicine highlights how pharmacology precisely targets brain regions, revealing patterns that even mirror those seen in brain disorders.
Abstract
Abstract To understand how pharmacological interventions can exert their powerful effects on brain function, we need to understand how they engage ...
Recruitment discrimination of lifetime classic psychedelic users is unjustified: Evidence from employees' motivation-based workplace absenteeism
Journal of Psychedelic Studies – January 16, 2023
Summary
Despite widespread stigma, prior psilocybin and other psychedelic use does not predict workplace absenteeism. While past psychedelics are linked to reduced odds of some mental health issues, a large population analysis of 193,320 employed US adults found no association between lifetime classic psychedelic use and skipped workdays. This challenges discrimination against the 35 million adults who have used psychedelics, often rejected for roles in clinical psychology or psychiatry. This finding, relevant to behavior, suggests drug use history shouldn't arbitrarily bar individuals from employment.
Abstract
Abstract Background and aims Although large-scale population studies have linked the use of classic psychedelics (lysergic acid diethylamide, psilo...
Psychedelics and Mindfulness: A Systematic Review and Meta-Analysis
OpenAlex – October 11, 2021
Summary
Psychedelics, including alkaloids like psilocybin and ayahuasca, significantly boost mindfulness, particularly acceptance, non-judgement of inner experience, and non-reactivity. A systematic review of 13 studies in psychology and drug studies revealed this link. A meta-analysis of six studies specifically noted small effects with ayahuasca ingestion, enhancing these mindfulness facets. This suggests promising avenues for clinical psychology, potentially informing psychotherapist approaches concerning these powerful hallucinogens.
Abstract
Background and Aims: The benefits of classic serotonergic psychedelics (e.g. psilocybin, LSD, DMT, ayahuasca) are becoming more widely known with t...
Modeling Retention Behavior on Analysis of Hallucinogenic Mushrooms Using Hydrophilic Interaction Liquid Chromatography
Journal of Chromatographic Science – November 15, 2018
Summary
Hallucinogenic compounds like psilocin and psilocybin from a truffle-like fungus are effectively separated using advanced Chemistry techniques. Three hydrophilic interaction chromatography (HILIC) columns, a type of High-performance liquid chromatography, proved suitable for isolating these natural products. Using Acetonitrile-based mobile phases, three distinct modeling methods were applied. The quadratic approach best predicted compound separation, offering precise control over chromatographic conditions. This work advances Analytical Chemistry and Chromatography, providing robust methods for analyzing complex natural product extracts.
Abstract
The goal of this work was to investigate and compare the selectivity of three different hydrophilic interaction liquid chromatography (HILIC) charg...
Microcrystalloptic tests for lysergic acid diethylamide and other hallucinogens
Journal of Pharmacy and Pharmacology – November 01, 1970
Summary
Accurately identifying illicit hallucinogens like Psilocybin and Lysergic acid diethylamide (LSD) presents a persistent challenge in forensic toxicology. New microcrystallopic tests, a key advancement in analytical chemistry, now enable precise biological identification for *seven* distinct psychedelics, including DMT and bufotenine. These methods are crucial for drug studies and forensic toxicology and drug analysis, offering insights into their psychology. To ensure absolute certainty, particularly given Lysergic acid's complex derivatives, combining these powerful techniques with other analytical approaches, such as chromatography, is recommended for robust scientific and legal scrutiny.
Abstract
Abstract Microcrystallopic tests for LSD, NN-diethyltryptamine, NN-dimethyltryptamine, bufotenine, psilocin, psilocybin and STP are described. The ...
Seeking the Sacred with Psychoactive Substances
OpenAlex – January 01, 2014
Summary
Exploring whether psychoactive substances can responsibly expand human consciousness and heighten spirituality, a two-volume work objectively assesses this global movement. Covering substances like psilocybin and ayahuasca, it examines their historical and medical use across diverse faiths—Christianity, Islam, Buddhism, and Shamanism. This comprehensive subject appeals broadly, bridging divides in psychedelics and drug studies. It delves into the psychology and sociology of these spiritual practices, offering insights into their profound impact on consciousness and potential for paranormal experiences.
Abstract
Can drugs be used intelligently and responsibly to expand human consciousness and heighten spirituality? This two-volume work presents objective sc...
Could Psychedelics Treat Neuropathic Chronic Pain?
Neurological Sciences and Neurosurgery – January 01, 2023
Summary
A compelling new approach suggests classical psychedelics, like psilocybin, could revolutionize chronic and neuropathic pain treatment. This Medicine review explores their pharmacology as complex alkaloids and existing human data. Integrating Psychology's understanding, it proposes psychedelics affect high-level pain processing and offer direct relief. Such drug studies, alongside research into targets like nicotinic acetylcholine receptors, are crucial for advancing pain management.
Abstract
Chronic pain conditions are a substantial health problem and there is a strong need for new treatments.We hypothesise that classical psychedelics s...
Psychedelics in the Treatment of Substance Use Disorders
Psychiatric Annals – September 01, 2022
Summary
Psychedelics like psilocybin and lysergic acid diethylamide show significant promise for treating addiction, including alcohol, opioid, and tobacco use disorders. Growing evidence from observational studies and clinical trials suggests these hallucinogens, influencing neurotransmitter receptors, may facilitate profound psychological shifts. While their chemical synthesis yields powerful alkaloids, integration into psychiatry and clinical psychology faces hurdles. Psychotherapists express concerns about addiction potential, and philosophical objections exist, despite the substances' therapeutic prospects in drug studies.
Abstract
Growing evidence from observational studies and clinical trials suggests that psychedelics such as lysergic acid diethylamide, 3,4-methylenedioxyme...
Psychedelic-assisted therapy for anxiety and depression in the face of death: A critical review with an anthropological lens
Journal of Psychedelic Studies – February 25, 2019
Summary
Psilocybin shows profound promise in medicine, significantly reducing anxiety and distress for terminally ill patients facing death anxiety. Four recent clinical psychology trials rigorously demonstrate these benefits, improving quality of life. While the therapeutic impact of these psychedelics and drug studies is clear, gaps remain in understanding the existential meaning of death and how these chemical synthesis and alkaloids exert their Neurotransmitter Receptor Influence on Behavior. Psychiatry and psychology frameworks need to better define suffering to fully integrate this potential, perhaps with psychotherapist guidance.
Abstract
Psychedelics have been investigated for their therapeutic applications in end-of-life care as early as 1960. Recently, there have been four main gr...
Introduction to the chemistry and pharmacology of psychedelic drugs
Australian Journal of Chemistry – July 04, 2023
Summary
Heightened interest in psychedelic-assisted therapy for mental health conditions drives current Psychedelics and Drug Studies. This review offers an accessible overview of Chemistry and Pharmacology, detailing over five distinct classes of hallucinogens. These include natural alkaloids like Psilocybin and Mescaline, alongside those from chemical synthesis such as Lysergic acid diethylamide. Understanding their Neurotransmitter Receptor Influence on Behavior is crucial for advancing Psychology and therapeutic applications.
Abstract
The science of psychedelics is an intriguing, multi-disciplinary field that has recently been the subject of heightened public interest. This has m...
Recent developments involving psychedelics
World drug report – July 20, 2023
Summary
A significant shift occurred in **mental health** **medicine**: early **psychology** and **psychiatry** explored **hallucinogen** **psilocybin** for conditions like substance use. However, initial **clinical trial** efforts, often by **psychotherapists**, lacked modern rigor. By **1971**, international controls on **psychedelics** emerged. Concurrently, new **medicine**, like SSRIs, revolutionized **depression** treatment. These advancements, demonstrating **neurotransmitter receptor influence on behavior**, offered proven efficacy for complex **mental health** disorders, shifting **clinical psychology** away from early **drug studies** involving **alkaloids**.
Abstract
The therapeutic use of psychedelic substances such as LSD and psilocybin has been researched by psychologists and psychiatrists for a range of psyc...
Psychotherapy with the aid of LSD
Nordic Journal of Psychiatry – January 01, 1996
Summary
Patients undergoing early psychedelic medicine treatments for psychiatric diagnosis experienced significantly longer hospital stays. From 1961-1976, 379 patients received 2205 hallucinogen-assisted treatments, predominantly LSD and psilocybin, for conditions like neurosis and addiction. Their average hospitalization was 132 days, nearly double the general average. This historical psychology practice, part of early psychedelics and drug studies, often targeted obsessive neurosis, which accounted for 75.6% of diagnoses in later years, highlighting its role in psychiatry.
Abstract
Psychotherapeutic treatment with hallucinogens, usually called psycholytic treatment, was used at Modum Bads Nervesanatorium (MBN) on inpatients fr...
9 Signs You Need Help With Magic Mushrooms uk
OpenAlex – July 16, 2022
Summary
Psilocybin alleviates distress through profound feelings of affection and unity. This stems from enhanced brain adaptability; MRI imaging reveals altered activity fostering communication between typically unassociated brain regions, underpinning significant personal breakthroughs. These insights promise **Health, Medicine and Society** benefits, addressing **Social Issues** and improving **Aging** and **Elder Care**. Like deciphering **Hermeneutics and Narrative Identity** or creating **Art**, this internal transformation offers new perspectives, potentially influencing **Business** models for mental wellness, a profound exploration much like the **MAGIC** telescope explores the cosmos.
Abstract
According to researchers, magic mushrooms ease pressure and distress mainly because of the feeling of affection and remaining "a single&am...
Hallucinogen Persistent Perception Disorder Induced by New Psychoactive Substituted Phenethylamines; A Review with Illustrative Case
Current Psychiatry Reviews – August 10, 2016
Summary
The first documented case of Hallucinogen Persistent Perception Disorder (HPPD) caused by a high dose of 2C-E, a modern designer drug, highlights an emerging concern in Psychiatry. While HPPD is known from traditional psychoactive substances like Lysergic acid diethylamide, Psilocybin (a Tryptamine), and Mescaline, this Phenethylamine-class substance presents new challenges for Medicine. The individual's persistent visual disturbances, a focus of Psychology and Psychedelics and Drug Studies, were effectively blunted by lamotrigine. This case, often identified via Forensic Toxicology and Drug Analysis, signals evolving risks from novel hallucinogens.
Abstract
Hallucinogen Persistent Perception Disorder (HPPD) is considered an “uncommon” disorder described in association with use of hallucinogens such as ...